6 active not recruiting. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 6 |
| Phase 1 | 3 | Active not recruiting 3 |
Follow berzosertib: new trials by email Literature Review of berzosertib trials Research Report on berzosertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers Lurbinectedin, Berzosertib - SCLC, Small Cell Cancer | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 37 | 2021-06-01 | 2026-03-17 |
| Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer Berzosertib, Biospecimen Collection, Carboplatin - Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 12 | 2021-04-14 | 2026-09-21 |
| Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors Avelumab, Berzosertib - Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 23 | 2020-03-17 | 2026-06-11 |
| Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs Berzosertib, Biopsy Procedure, Biospecimen Collection - Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 104 | 2019-12-30 | 2026-07-31 |
| M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Berzosertib, Carboplatin, Docetaxel - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 73 | 2019-05-29 | 2026-10-09 |
| Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Berzosertib, Gemcitabine, Gemcitabine Hydrochloride - Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 70 | 2016-08-25 | 2026-09-09 |
Small Cell Lung Carcinoma (2) · Fallopian Tube Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1)
National Cancer Institute (NCI) (5) · M.D. Anderson Cancer Center (1)
United States (6)
Anish Thomas, M.D. (1) · Arun Rajan (1) · Atish D Choudhury (1) · Liza C Villaruz (1) · Panagiotis A Konstantinopoulos (1) · Timothy A Yap (1)
PMID 32553118, PMID 37491889, PMID 37824137, PMID 38635934, PMID 41206673, PMID 42820295
UM1CA186709 (2), UM1CA186690 (1), ZIABC011078 (1)